SAN DIEGO, Nov. 25, 2014 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive
Officer of Neurocrine Biosciences, will be presenting at two
investor conferences next week.
On December 2 at 11:40am Eastern Time (8:40am Pacific Time) he will make a presentation
at the 2014 Deutsche Bank BioFEST in Boston.
On December 3 at 12:00pm Eastern Time (9:00am Pacific Time) he will make a presentation
at the 26th Annual Piper Jaffray Healthcare Conference
in New York City.
Listeners are encouraged to visit the website approximately 5
minutes prior to the presentation to download or install any
necessary software. A replay of the presentation will be
available on the website approximately one hour after the
conclusion of the event and will be archived for one month.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and a wholly owned vesicular
monoamine transporter 2 inhibitor for the treatment of movement
disorders. Neurocrine intends to maintain certain commercial rights
to its VMAT2 inhibitor for evolution into a fully-integrated
pharmaceutical company. Neurocrine Biosciences, Inc. news
releases are available through the Company's website via the
internet at http://www.neurocrine.com.
SOURCE Neurocrine Biosciences, Inc.